We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -32.25 | -4.15% | 744.50 | 778.08 | 754.29 | 778.08 | 3,258,550 | 01:00:00 |
From May 2019 to May 2024
By Adriano Marchese
Eli Lilly & Co. said Wednesday that it has submitted new data in its request for an emergency authorization from the Food and Drug Administration for its drug bamlanivimab to treat mild cases of Covid-19.
The Indianapolis-based company said that it has included in the submission data published by the New England Journal of Medicine from a Phase 2 study on the drug.
"The publication of these data in a peer-reviewed journal adds to the growing body of evidence for the potential utility for neutralizing antibodies as therapeutics for people recently diagnosed with mild to moderate COVID-19, particularly high-risk patients," said Ajay Nirula, vice president of immunology and co-first author of the study.
The Phase 2 study was designed to assess the efficacy and safety of bamlanivimab alone for the treatment of symptomatic Covid-19 in the outpatient setting, the company said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 28, 2020 17:58 ET (21:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
